InvestorsHub Logo
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

Re: enemem post# 34876

Thursday, 11/18/2010 2:55:20 PM

Thursday, November 18, 2010 2:55:20 PM

Post# of 48499
Bladerunner is absolutely correct. Cortex doesn't yet have a hi-impact in the clinic, and only North American (plus sundry) rights for the Servier compound--which has yet to complete a Phase I trial. They might get $5 million upfront for a high-impact deal that is strictly preclinical.

NeuroInvestment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News